EGFR and non-small cell lung carcinoma: Indeed, the anti-PD-(L)1 monotherapy has been shown to have minimal activity in EGFR-mutant NSCLC and therefore should only be considered after all other therapies that have been shown to be more effective in this patient population, such as EGFR-TKIs, platinum-doublet chemotherapy, and probably docetaxel plus anti-angiogenic drug (Ramucirumab®), have been exhausted.